|
1
|
Henson DE, Albores-Saavedra J and Corle D:
Carcinoma of the gallbladder. Histologic types, stage of disease,
grade, and survival rates. Cancer. 70:1493–1497. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Japan VSo, Tokyo (Japan). Japanese
Ministry of Health and Welfare. Statistics Assoc; 1998
|
|
3
|
Cubertafond P, Gainant A and Cucchiaro G:
Surgical treatment of 724 carcinomas of the gallbladder. Results of
the French Surgical Association Surgery. Ann Surg. 219:275–280.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rückert JC, Rückert RI, Gellert K, Hecker
K and Müller JM: Surgery for carcinoma of the gallbladder.
Hepatogastroenterology. 43:527–533. 1996.
|
|
5
|
Pandey M and Shukla VK: Diet and
gallbladder cancer: a case-control study. Eur J Cancer Prev.
11:365–368. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lowenfels AB, Lindström CG, Conway MJ and
Hastings PR: Gallstones and risk of gallbladder cancer. J Natl
Cancer Inst. 75:77–80. 1985.PubMed/NCBI
|
|
7
|
Kimura K, Ohto M, Saisho H, Unozawa T,
Tsuchiya Y, Morita M, Ebara M, Matsutani S and Okuda K: Association
of gallbladder carcinoma and anomalous pancreaticobiliary ductal
union. Gastroenterology. 89:1258–1265. 1985.PubMed/NCBI
|
|
8
|
Suzuki T, Takano Y, Kakita A and Okudaira
M: An immunohistochemical and molecular biological study of
c-erbB-2 amplification and prognostic relevance in gallbladder
cancer. Pathol Res Pract. 189:283–292. 1993. View Article : Google Scholar
|
|
9
|
Yukawa M, Fujimori T, Hirayama D, Idei Y,
Ajiki T, Kawai K, Sugiura R, Maeda S and Nagasako K: Expression of
oncogene products and growth factors in early gallbladder cancer,
advanced gallbladder cancer, and chronic cholecystitis. Hum Pathol.
24:37–40. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kiguchi K, Carbajal S, Chan K, Beltrán L,
Ruffino L, Shen J, Matsumoto T, Yoshimi N and DiGiovanni J:
Constitutive expression of ErbB-2 in gallbladder epithelium results
in development of adenocarcinoma. Cancer Res. 61:6971–6976.
2001.PubMed/NCBI
|
|
11
|
Di Marco E, Pierce JH, Knicley CL and Di
Fiore PP: Transformation of NIH 3T3 cells by overexpression of the
normal coding sequence of the rat neu gene. Mol Cell Biol.
10:3247–3252. 1990.PubMed/NCBI
|
|
12
|
Kiguchi K, Bol D, Carbajal S, Beltrán L,
Moats S, Chan K, Jorcano J and DiGiovanni J: Constitutive
expression of erbB2 in epidermis of transgenic mice results
in epidermal hyperproliferation and spontaneous skin tumor
development. Oncogene. 19:4243–4254. 2000.
|
|
13
|
Klapper LN, Kirschbaum MH, Sela M and
Yarden Y: Biochemical and clinical implications of the ErbB/HER
signaling network of growth factor receptors. Adv Cancer Res.
77:25–79. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schroeder JA, Thompson MC, Gardner MM and
Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor
receptor and correlates with mitogen-activated protein kinase
activation in the mouse mammary gland. J Biol Chem.
276:13057–13064. 2001. View Article : Google Scholar
|
|
15
|
Jepson S1, Komatsu M, Haq B, Arango ME,
Huang D, Carraway CA and Carraway KL: Muc4/sialomucin complex, the
intramembrane ErbB2 ligand, induces specific phosphorylation of
ErbB2 and enhances expression of p27kip, but does not
activate mitogen-activated kinase or protein kinaseB/Akt pathways.
Oncogene. 21:7524–7532. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carraway KL, Ramsauer VP, Haq B and
Carothers Carraway CA: Cell signaling through membrane mucins.
Bioessays. 25:66–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carraway KL III, Rossi EA, Komatsu M,
Price-Schiavi SA, Huang D, Guy PM, Carvajal ME, Fregien N, Carraway
CA and Carraway KL: An intramembrane modulator of the ErbB2
receptor tyrosine kinase that potentiates neuregulin signaling. J
Biol Chem. 274:5263–5266. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buisine MP, Devisme L, Degand P, Dieu MC,
Gosselin B, Copin MC, Aubert JP and Porchet N: Developmental mucin
gene expression in the gastroduodenal tract and accessory digestive
glands. II Duodenum and liver, gallbladder, and pancreas. J
Histochem Cytochem. 48:1667–1676. 2000. View Article : Google Scholar
|
|
19
|
Miyahara N, Shoda J, Ishige K, Kawamoto T,
Ueda T, Taki R, Ohkohchi N, Hyodo I, Thomas MB, Krishnamurthy S,
Carraway KL and Irimura T: MUC4 interacts with ErbB2 in human
gallbladder carcinoma: potential pathobiological implications. Eur
J Cancer. 44:1048–1056. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shibahara H, Tamada S, Higashi M, Goto M,
Batra SK, Hollingsworth MA, Imai K and Yonezawa S: MUC4 is a novel
prognostic factor of intrahepatic cholangiocarcinoma-mass forming
type. Hepatology. 39:220–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Braissant O and Wahli W: A simplified in
situ hybridization protocol using non-radioactively labelled probes
to detect abundant and rare mRNAs on tissue sections. Biochemica.
1:10–16. 1998.
|
|
22
|
Kawamoto T, Kiguchi K, Ruffino L, Dudek D,
Ajiki T, Thomas M and Digiovanni J: Role of ErbB2 in the
development of gallbladder cancer. Tando. 19:550–556. 2005.(In
Japanese).
|
|
23
|
Vadlamudi R, Mandal M, Adam L, Steinbach
G, Mendelsohn J and Kumar R: Regulation cyclooxygenase-2 pathway by
HER2 receptor. Oncogene. 18:305–314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qian X, LeVea CM, Freeman JK, Dougall WC
and Greene MI: Heterodimerization of epidermal growth factor
receptor and wild-type or kinase-deficient Neu: a mechanism of
interreceptor kinase activation and transphosphorylation. Proc Natl
Acad Sci USA. 91:1500–1504. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Murali R, Brennan PJ, Kieber-Emmons T and
Greene MI: Structural analysis of p185c-neu and
epidermal growth factor receptor tyrosine kinases: oligomerization
of kinase domains. Proc Natl Acad Sci USA. 93:6252–6257. 1996.
|
|
26
|
Ukita Y, Kato M and Terada T: Gene
amplification and mRNA and protein overexpression of c-erbB-2
(HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by
fluorescence in situ hybridization, in situ hybridization, and
immunohistochemistry. J Hepatol. 36:780–785. 2000. View Article : Google Scholar
|
|
27
|
Suzuki H, Isaji S, Pairojkul C and
Uttaravichien T: Comparative clinicopathological study of resected
intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J
Hepatobiliary Pancreat Surg. 7:206–211. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kiguchi K, Ruffino L, Kawamoto T, Ajiki T
and Digiovanni J: Chemopreventive and therapeutic efficacy of
orally active tyrosine kinase inhibitors in a transgenic mouse
model of gallbladder carcinoma. Clin Cancer Res. 11:5572–5580.
2005. View Article : Google Scholar
|
|
29
|
Lenferink AE, Pinkas-Kramarski R, van de
Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van
Zoelen EJ and Yarden Y: Differential endocytic routing of homo- and
hetero-dimeric ErbB tyrosine kinases confers signaling superiority
to receptor heterodimers. EMBO J. 17:3385–3397. 1998. View Article : Google Scholar
|
|
30
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signaling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Komatsu M, Jepson S, Arango ME, Carothers
Carraway CA and Carraway KL: Muc4/sialomucin complex, an
intramembrane modulator of ErbB2/HER2/Neu, potentiates primary
tumor growth and suppresses apoptosis in a xenotransplanted tumor.
Oncogene. 20:461–470. 2001. View Article : Google Scholar
|
|
32
|
Price-Schiavi SA, Jepson S, Li P, Arango
M, Rudland PS, Yee L and Carraway KL: Rat Muc4 (sialomucin complex)
reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a
potential mechanism for herceptin resistance. Int J Cancer.
99:783–791. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Balagué C, Audié JP, Porchet N and Real
FX: In situ hybridization shows distinct patterns of mucin gene
expression in normal, benign, and malignant pancreas tissues.
Gastroenterology. 109:953–964. 1995.PubMed/NCBI
|
|
34
|
Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt
JL, Holt SE, Rozich RA, Hixson DC and Sirica AE: erbB-2/neu
transformed rat cholangiocytes recapitulate key cellular and
molecular features of human bile duct cancer. Gastroenterology.
129:2047–2057. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshida S, Naito K, Hori A, Teratani M,
Koyama M, Tasaka A and Terashita Z: TAK-165, a selective inhibitor
of HER2 tyrosine kinase: 2. Mechanism of antitumor activity on HER2
signal transduction pathway. Proc Am Assoc Cancer Res.
43:7862003.
|
|
36
|
Kamei D, Murakami M, Nakatani Y, Ishikawa
Y, Ishii T and Kudo I: Potential role of microsomal prostaglandin E
synthase-1 in tumorigenesis. J Biol Chem. 278:19396–19405. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sirica AE, Lai GH, Endo K, Zhang Z and
Yoon BI: Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma:
potential therapeutic targets. Semin Liver Dis. 22:303–313. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lai GH, Zhang Z and Sirica AE: Celecoxib
acts in a cyclooxygenase-2-independent manner and in synergy with
emodin to suppress rat cholangiocarcinoma growth in vitro through a
mechanism involving enhanced Akt inactivation and increased
activation of caspases-9 and -3. Mol Cancer Ther. 2:265–271.
2003.
|
|
39
|
Itoi T, Watanabe H, Ajioka Y, Oohashi Y,
Takei K, Nishikura K, Nakamura Y, Horil A and Saito T: APC, K-ras
codon 12 mutations and p53 gene expression in carcinoma and adenoma
of the gallbladder suggest two genetic pathways in gallbladder
carcinogenesis. Pathol Int. 46:333–340. 1996. View Article : Google Scholar : PubMed/NCBI
|
